Trends in Pharmacological Sciences
ReviewAdoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Section snippets
The Rise of Adoptive T Cell Cancer Therapies
The success of adoptive T cell therapies, using genetically engineered receptors against cancer antigens, has recently gained the interest of biotechnology and pharmaceutical companies [1]. Much of the attention has focused on synthetic receptors now commonly referred to as CARs. CARs typically link an extracellular, antigen-recognition molecule comprising antibody domains (a single-chain Fv, scFv, containing the variable domains of the light and heavy chains; see Glossary), a stalk-like
TCR: Structure and Signaling
The TCR is an αβ heterodimer that binds to a short peptide bound to a product of the MHC. Each αβ subunit contains variable (V) and constant (C) region domains, and the latter is followed by a transmembrane region. Each V domain contains three loops, called complementarity-determining regions (CDR1, CDR2, and CDR3), which interact with the peptide (pep)MHC antigen. The conserved docking angle of the six CDRs over the pepMHC antigen is thought to confer maximal signaling capabilities and it
Chimeric Antigen Receptor: Structure and Signaling
Chimeric antigen receptors (CARs) represent a class of synthetic constructs typically comprising a single-chain antibody fragment (scFv, VH-linker-VL, or VL-linker-VH), an extracellular stalk (hinge) domain, a transmembrane domain, and one or more intracellular signaling domains 5, 39 (Figure 1). The scFv endows T cells with the ability to respond to cell surface antigens independent of MHC. The CAR format provides an opportunity to potentially exploit (or repurpose) many of the scFv that have
Sensitivity of TCRs and CARs: Impact of Affinity, Receptor Density, and Antigen Density
As emphasized above, based simply on their design, the mechanism by which CAR binding to its cognate antigen leads to T cell activation differs in substantial ways from the mechanism by which TCR binding leads to T cell activation. Even without consideration of co-stimulatory molecules (CD28 and 4-1BB), TCRs mediate activity through a complex of ten subunits that are poised to be triggered by low numbers of pepMHC antigens, and through the action of the coreceptors CD4 and CD8 11, 12, 13 (Box 1
Adoptive T Cell Therapy: Clinical Outcomes Using TCRs and CARs
Early clinical data from adoptive T cell trials using TCRs and CARs have demonstrated the tremendous potential of redirected T cells in the control of tumors. Some of the most exciting results have come from trials using CAR T cells against hematological cancers. As described in recent reviews 1, 3, 4, the variability in scFv fragments, co-stimulatory domains, and methods of gene transfer (such as retrovirus, lentivirus, or other newly developed techniques), have made it difficult to compare
Concluding Remarks
Adoptive T cell therapies using engineered receptors that bind to cancer antigens have received much attention due to early clinical successes. The two major formats of these receptors target different types of antigen. TCRs target the natural ligands for T cells: cancer-associated peptides bound to an MHC product. Optimization of these receptors for adoptive T cell therapies will typically require raising the affinity above the normal levels [92] to mediate the activities of both CD8 and CD4 T
Acknowledgments
We thank past and present members of the lab for their contributions over the years and, in particular, we thank Jennifer Stone and Adam Chervin for helpful discussions. This work was supported by NIH grants CA178844, CA187592, and CA180723.
Glossary
- 4-1BB
- a co-stimulatory molecule (also known as CD137) expressed on the surface of T cells. 4-1BB promotes the expression of the antiapoptotic factors, such as BCL-2, BCL-XL, and BCL2A1.
- CD3
- a cell-surface molecule expressed on T cells. CD3 subunits associate with the T cell receptor αβ heterodimer and contain intracellular signaling motifs for T cell activation. Three CD3 heterodimers (CD3ɛγ, CD3ɛδ, and CD3ζζ) occur within each TCR/CD3 complex.
- CD4
- a coreceptor molecule expressed on the surface of
References (98)
- et al.
Designing chimeric antigen receptors to effectively and safely target tumors
Curr. Opin. Immunol.
(2015) - et al.
The role of T cell receptor signaling thresholds in guiding T cell fate decisions
Curr. Opin. Immunol.
(2015) Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response
Immunity
(1996)A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells
Immunity
(2013)CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse
Nat. Immunol.
(2004)Dynamics of p56lck translocation to the T cell immunological synapse following agonist and antagonist stimulation
Immunity
(2002)Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif
Cell
(2008)Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation
Cell
(2002)Antigen ligation triggers a conformational change within the constant domain of the alphabeta T cell receptor
Immunity
(2009)The alphabeta T cell receptor is an anisotropic mechanosensor
J. Biol. Chem.
(2009)
Targeting cancer-specific mutations by T cell receptor gene therapy
Curr. Opin. Immunol.
Improving the efficacy and safety of engineered T cell therapy for cancer
Cancer Lett.
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells
Mol. Ther.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Blood
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
Mol. Ther.
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication
Mol. Ther.
Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity
Mol. Immunol.
Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity
Mol. Ther.
The interplay of effector and regulatory T cells in cancer
Curr. Opin. Immunol.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lancet
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity
Mol. Ther.
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
Mol. Ther.
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
Mol. Ther.
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Blood
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Blood
TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity
Curr. Opin. Immunol.
Adoptive cellular therapy: a race to the finish line
Sci. Transl. Med.
Re-adapting T cells for cancer therapy: from mouse models to clinical trials
Immunol. Rev.
Chimeric antigen receptor T cells for cancer immunotherapy
J. Clin. Oncol.
CD19 CAR therapy for acute lymphoblastic leukemia
Am. Soc. Clin. Oncol. Educ. Book
How TCRs bind MHCs, peptides, and coreceptors
Annu. Rev. Immunol.
Dynamics of cell surface molecules during T cell recognition
Annu. Rev. Biochem.
Molecular architecture of the alphabeta T cell receptor-CD3 complex
Proc. Natl. Acad. Sci. U.S.A.
Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation
Science
Direct observation of ligand recognition by T cells
Nature
T cell killing does not require the formation of a stable mature immunological synapse
Nat. Immunol.
CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery
Proc. Natl. Acad. Sci. U.S.A.
A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8
Science
Ligand-engaged TCR is triggered by Lck not associated with CD8 coreceptor
Nat. Commun.
Mechanisms for T cell receptor triggering
Nat. Rev. Immunol.
Nonstimulatory peptides contribute to antigen-induced CD8-T cell receptor interaction at the immunological synapse
Nat. Immunol.
Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity
Nature
Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response
Proc. Natl. Acad. Sci. U.S.A.
Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3
Proc. Natl. Acad. Sci. U.S.A.
Cutting Edge: mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling
J. Immunol.
The kinetic-segregation model: TCR triggering and beyond
Nat. Immunol.
Biophysical mechanism of T-cell receptor triggering in a reconstituted system
Nature
Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
Annu. Rev. Immunol.
The B7 family revisited
Annu. Rev. Immunol.
Cited by (167)
Biophysical and mechanobiological considerations for T-cell-based immunotherapy
2023, Trends in Pharmacological SciencesHarnessing sortase A transpeptidation for advanced targeted therapeutics and vaccine engineering
2023, Biotechnology AdvancesAdoptive transfer of activated immune cells against solid tumors: A preliminary study
2022, Cellular ImmunologyNano-drug delivery systems for T cell-based immunotherapy
2022, Nano Today